Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mimopezil (Debiopharm)
- Development stage
- Unknown
- Lead developer
- Debiopharm
- Modality
- Small Molecules
- Administration
- Oral, Subcutaneous, Implant
01
Overview
ZT-1 (mimopezil) is a small molecule prodrug of huperzine A, a reversible and selective acetylcholinesterase (AChE) inhibitor originally derived from the Chinese herb *Huperzia serrata*. Developed by Debiopharm, ZT-1 is a Schiff base derivative designed to improve the pharmacokinetic profile and safety of huperzine A for the treatment of Alzheimer's disease. Upon administration, ZT-1 is rapidly absorbed and converted into its active metabolite, huperzine A, which increases acetylcholine levels in the brain by inhibiting its degradation. Clinical development has explored both oral formulations and a monthly subcutaneous sustained-release implant (the BRAINz study), the latter intended to provide continuous drug delivery, improve patient compliance, and reduce the variability in drug exposure compared to daily oral AChE inhibitors.
- Other names
- N-[2-hydroxy-3-methoxy-5-chlorobenzylidene] huperzine A
02
Targets
AcetylcholinesteraseNMDAR (Glutamate receptor ionotropic, NMDA)
Beyond the preview
Go deeper on mimopezil (Debiopharm).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mimopezil (Debiopharm).